Discovery of a Tat HIV-1 Inhibitor through Computer-Aided Drug Design
Author(s) -
Didier Esquieu,
JeanMarie Péloponèse,
Sandrine Opi,
Catherine Grégoire,
Jean de Mareuil,
Jennifer Watkins,
Grant R. Campbell,
Jean-Pierre Dunot,
James N. Sturgis,
Myriam Witvrouw,
Christophe Pannecouque,
Erik De Clercq,
Mickaël Montembault,
Giang VoThanh,
Monique Villiéras,
Valérie Fargeas,
Jacques Lebreton,
Erwann Loret
Publication year - 2003
Publication title -
journal of spectroscopy
Language(s) - English
Resource type - Journals
eISSN - 2314-4920
pISSN - 2314-4939
DOI - 10.1155/2003/283731
Subject(s) - drug , human immunodeficiency virus (hiv) , drug discovery , pharmacology , computer science , medicine , virology , chemistry , biochemistry
Tat is a regulatory HIV-1 protein, which has the particularity to be secreted very early by HIV-infected cells. The extra cellular roles of Tat are suspected to be the main cause of the maintenance of reservoirs of HIV-infected cells and the failure of actual AIDS therapies to eradicate HIV. This study describes the rationale used to design molecules that bind to a target area containing an hydrophobic pocket identified in the 2D-NMR structure of Tat. Molecules were synthesized and the derivative named TDS2 was shown to be a Tat inhibitor. Fluorescence revealed that TDS2 binds in the target area, which is conserved across five different Tat variants representative of the main HIV-1 subtypes. TDS2 inhibited in vitro HIV-1 replication in human T-cells. Further chemical modifications remain necessary to enhance affinity to Tat and reduce cytotoxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom